Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$74.83 USD

74.83
1,017,925

-0.25 (-0.33%)

Updated Sep 20, 2024 04:00 PM ET

After-Market: $74.78 -0.05 (-0.07%) 6:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (68 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now

Investor confidence in Tandem Diabetes (TNDM) stock is at a high, thanks to solid prospects.

Walgreens, UnitedHealthcare Team Up to Boost Medicare Services

Walgreens (WBA) partners with UnitedHealthcare to further strengthen the Medicare coverage for its customers.

Here's Why You Should Buy Thermo Fisher (TMO) Stock Now

Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar performance.

NuVasive Gets FDA Nod for CoRoent Small Interlock System

NuVasive (NUVA) receives the FDA clearance for expanded use of its Interlock system for minimally disruptive spine surgery at multiple levels.

Omnicell (OMCL) Rides on Global Expansion, Strategic R&Ds

Omnicell's (OMCL) diligent focus on product innovation through R&D is encouraging.

Henry Schein to Showcase New Dental Offerings at GNYDM

Henry Schein's (HSIC) suite of solutions, education, & social media activity featuring dental industry leaders to enable dental professionals to explore new options revolutionizing digital dentistry.

Myriad's BRACAnalysis Wins HBOC Risk Assessment Nod in Japan

The latest approval of Myriad Genetics' (MYGN) BRACAnalysis for HBOC risk assessment in Japan will further validate the superior standard of the BRACAnalysis Diagnostic System, globally.

Dexcom (DXCM) Hits a 52-Week High: What's Driving the Stock?

Dexcom (DXCM) gains from several positive developments.

Myriad Genetics' Test Added in Disease Activity Measure List

Myriad Genetics' (MYGN) Vectra test receives recognition, with the inclusion in the list of recommended disease activity measures for RA patients.

Hologic (HOLX) Set to Divest Medical Aesthetics Business

Hologic (HOLX) to sell off its medical aesthetics business to focus on other core segments.

Haemonetics Launches TEG 6s PlateletMapping Assay Cartridge

The global commercial availability of the cartridge is likely to bolster Haemonetics' (HAE) TEG portfolio.

3 Reasons Why Growth Investors Shouldn't Overlook Haemonetics (HAE)

Haemonetics (HAE) could produce exceptional returns because of its solid growth attributes.

QIAGEN Expands Existing Deal With LabCorp for Better Treatment

QIAGEN (QGEN) announces the expansion of partnership with LabCorp (LH) to make genetic information available for clinical and research purposes.

Option Care is the Preferred Provider of Haemophilia Treatment

Option Care Health (BIOS) can currently access all hemophilia factor treatments.

Here's Why You Should Hold GNC Holdings (GNC) Stock for Now

Investors can still retain GNC Holdings (GNC) in their portfolio, thanks to solid prospects.

Safety Notice Issued by Boston Scientific (BSX) for AngioJet

Boston Scientific (BSX) issues an urgent field safety notice for AngioJet Ultra consoles.

Smith & Nephew's Study Outcomes for REGENETEN Encouraging

Smith & Nephew's (SNN) announces positive study outcomes for REGENETEN.

Zimmer (ZBH) Hits 52-Week High: What's Driving the Stock?

Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent positive developments.

Edwards Lifesciences (EW) Recalls PASCAL's Guide Sheath

Edwards Lifesciences (EW) issues a product recall for its guide sheath based on report from its urgent field safety notice.

InMode (INMD) Looks Good: Stock Adds 5.6% in Session

InMode (INMD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

QIAGEN Rides on Solid QuantiFERON-TB Sales Amid Several Woes

QIAGEN (QGEN) pins hopes on its key strategic collaborations with Hamilton Robotics and Tecan for the pre-analytical handling of blood tubes.

Amedisys Partners With nVoq to Improve Clinician Experience

Amedisys (AMED) aims to enhance clinician workflow by integrating nVoq's technology platform into its home health business.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for November 18th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.

Haemonetics (HAE) Grows on New Products, Robust Plasma Sales

Haemonetics (HAE) witnesses a steady uptick in Plasma franchise, fueled by favorable price, volume and mix.

Insulet (PODD) Hits a 52-Week High: What's Driving the Stock?

Insulet (PODD) has been gaining from several positive developments recently.